CLINICAL_TRIALS
trial_result
· 2014-10-01
Clinical Trial Update: 20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165) [Phase 2]
Summary
Amgen's Phase 2 study evaluating AMG 747 for negative symptoms of schizophrenia was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Schizophrenia | Phase 2 | Status: TERMINATED